Summary - ATAI - NASDAQ - Weiss Ratings

D

Atai Beckley N.V. ATAI

$4.41 $0.358.62% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$1.15 - $6.75

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion

11/25/2025 - Insider Monkey

AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i

11/24/2025 - Proactive Investors - UK

Enhanced Fortifies Executive Leadership Team & Board of Directors

11/20/2025 - PR Newswire

Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato

11/18/2025 - Insider Monkey

11 Must-Buy Penny Stocks to Buy Now

11/17/2025 - Insider Monkey

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

11/13/2025 - Globe Newswire

AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3

11/12/2025 - Proactive Investors - UK

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

11/12/2025 - Globe Newswire

AtaiBeckley's BPL-003 could redefine psychedelics dosing, analysts believe

11/11/2025 - Proactive Investors - UK

AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

11/11/2025 - Proactive Investors - UK

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

11/10/2025 - Market Exclusive

AtaiBeckley reports positive data supporting repeated dosing of BPL-003 in treatment-resistant depression patients

11/10/2025 - Proactive Investors - UK

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

11/10/2025 - Globe Newswire

Add Up The Parts: TMED Could Be Worth $36

11/10/2025 - ETF Channel

atai Life Sciences and Beckley Psytech complete strategic combination to form AtaiBeckley

11/5/2025 - Proactive Investors - UK

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

11/5/2025 - Globe Newswire

atai Life Sciences closes $149.5M public offering

10/21/2025 - Proactive Investors - UK

atai Life Sciences closes $149.5M public offering, extending cash runway into 2029

10/21/2025 - Proactive Investors - UK

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

10/20/2025 - Globe Newswire

atai Life Sciences to raise $130M in public stock offering

10/17/2025 - Proactive Investors - UK

Why Atai Life Sciences Stock Was So Lively This Week

10/17/2025 - Fool.com Headlines

atai Life Sciences Announces Pricing of Public Offering of Common Shares

10/17/2025 - Globe Newswire

atai Life Sciences and Beckley Psytech secure FDA Breakthrough Therapy Designation for BPL-003 in treatment-resistant depression

10/16/2025 - Proactive Investors - UK

atai Life Sciences Announces Proposed Public Offering of Common Shares

10/16/2025 - Globe Newswire

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

10/16/2025 - Globe Newswire

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Wednesday, November 12, 2025

Period Date

Tuesday, September 30, 2025

Next Filing

Week of Mar 16 and 20 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

--

52-week Low

Dec 18, 2024 - $1.15

52-week High

Oct 20, 2025 - $6.75

Valuation

Market Cap

$1.47B - Small Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.ataibeckley.com

Phone Number

31 20 793 2536

Address

Prof. J.H. Bavincklaan 7
Amstelveen, 1183 AT

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada... more